Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Corbus Pharmaceuticals stock | $1.02

Learn how to easily invest in Corbus Pharmaceuticals stock.

Corbus Pharmaceuticals Holdings Inc is a biotechnology business based in the US. Corbus Pharmaceuticals shares (CRBP) are listed on the NASDAQ and all prices are listed in US Dollars. Corbus Pharmaceuticals employs 76 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Corbus Pharmaceuticals

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – CRBP – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Corbus Pharmaceuticals stock price (NASDAQ: CRBP)

Use our graph to track the performance of CRBP stocks over time.

Corbus Pharmaceuticals shares at a glance

Information last updated 2021-10-16.
Latest market close$1.02
52-week range$0.91 - $4.00
50-day moving average $1.11
200-day moving average $1.54
Wall St. target price$2.05
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.75

Buy Corbus Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Corbus Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Corbus Pharmaceuticals price performance over time

Historical closes compared with the close of $1.02 from 2021-10-15

1 week (2021-10-08) -0.97%
1 month (2021-09-17) 1.02
3 months (2021-07-16) -31.08%
6 months (2021-04-16) -40.70%
1 year (2020-10-16) -8.11%
2 years (2019-10-17) -79.31%
3 years (2018-10-17) 7.52
5 years (2016-10-17) 6.95

Corbus Pharmaceuticals financials

Revenue TTM $2.7 million
Gross profit TTM $-94,329,983
Return on assets TTM -49.66%
Return on equity TTM -122.37%
Profit margin 0%
Book value $0.62
Market capitalisation $127.7 million

TTM: trailing 12 months

Shorting Corbus Pharmaceuticals shares

There are currently 6.6 million Corbus Pharmaceuticals shares held short by investors – that's known as Corbus Pharmaceuticals's "short interest". This figure is 7.2% down from 7.1 million last month.

There are a few different ways that this level of interest in shorting Corbus Pharmaceuticals shares can be evaluated.

Corbus Pharmaceuticals's "short interest ratio" (SIR)

Corbus Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Corbus Pharmaceuticals shares currently shorted divided by the average quantity of Corbus Pharmaceuticals shares traded daily (recently around 934222.66288952). Corbus Pharmaceuticals's SIR currently stands at 7.06. In other words for every 100,000 Corbus Pharmaceuticals shares traded daily on the market, roughly 7060 shares are currently held short.

However Corbus Pharmaceuticals's short interest can also be evaluated against the total number of Corbus Pharmaceuticals shares, or, against the total number of tradable Corbus Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Corbus Pharmaceuticals's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Corbus Pharmaceuticals shares in existence, roughly 50 shares are currently held short) or 0.0532% of the tradable shares (for every 100,000 tradable Corbus Pharmaceuticals shares, roughly 53 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Corbus Pharmaceuticals.

Find out more about how you can short Corbus Pharmaceuticals stock.

Corbus Pharmaceuticals share dividends

We're not expecting Corbus Pharmaceuticals to pay a dividend over the next 12 months.

Corbus Pharmaceuticals share price volatility

Over the last 12 months, Corbus Pharmaceuticals's shares have ranged in value from as little as $0.91 up to $4. A popular way to gauge a stock's volatility is its "beta".

CRBP.US volatility(beta: 1.94)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Corbus Pharmaceuticals's is 1.9402. This would suggest that Corbus Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Corbus Pharmaceuticals overview

Corbus Pharmaceuticals Holdings, Inc. , a clinical-stage pharmaceutical company, focuses on the development and commercialization of novel therapeutics that target the endocannabinoid system in the fields of autoimmunity, fibrosis, and cancer. Its lead product candidate is lenabasum, a cannabinoid receptor type 2 (CB2) that is in Phase III clinical trial for the treatment of dermatomyositis; and in Phase II clinical trial to treat systemic lupus erythematosus. The company is also developing cannabinoid receptor type 1 inverse agonist program for treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; and CB2 agonist program for the treatment of cancer. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, which includes the Jenrin library of approximately 600 compounds and multiple issued and pending patent filings; and strategic collaboration with Kaken Pharmaceutical Co. , Ltd. for the development and commercialization of lenabasum in Japan.

Frequently asked questions

What percentage of Corbus Pharmaceuticals is owned by insiders or institutions?
Currently 0.417% of Corbus Pharmaceuticals shares are held by insiders and 43.548% by institutions.
How many people work for Corbus Pharmaceuticals?
Latest data suggests 76 work at Corbus Pharmaceuticals.
When does the fiscal year end for Corbus Pharmaceuticals?
Corbus Pharmaceuticals's fiscal year ends in December.
Where is Corbus Pharmaceuticals based?
Corbus Pharmaceuticals's address is: 500 River Ridge Drive, Norwood, MA, United States, 02062
What is Corbus Pharmaceuticals's ISIN number?
Corbus Pharmaceuticals's international securities identification number is: US21833P1030
What is Corbus Pharmaceuticals's CUSIP number?
Corbus Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 21833P103

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site